Generation of minor histocompatibility antigen HA-1-specific cytotoxic T cells restricted by nonself HLA molecules: a potential strategy to treat relapsed leukemia after HLA-mismatched stem cell transplantation

被引:47
|
作者
Mutis, T
Blokland, E
Kester, M
Schrama, E
Goulmy, E
机构
[1] Leiden Univ, Med Ctr, Dept Immunohematol & Blood Transfus, NL-2333 ZA Leiden, Netherlands
[2] Leiden Univ, Med Ctr, Dept Hematol, NL-2333 ZA Leiden, Netherlands
关键词
D O I
10.1182/blood-2002-01-0024
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Successful stem cell transplantation (SCT) across HLA barriers can be performed with cord blood, megadoses of stem cells, or with nonmyeloablative conditioning strategies. Because the HLA-mismatched transplants are often T-cell depleted, leukemia relapse rates are high. Treatment of relapsed leukemia after HLA-mismatched SCT is difficult. A novel potential strategy to treat relapsed leukemia after HLA-mismatched SCT is the use of patients' mismatched HLA molecules as antigen-presenting molecules to generate hematopoietic system-specific cytotoxic T cells (CTLs) from the stem cell donor. Adoptive transfer of these hematopoetic system-specific CTLs that are restricted by nonself HLA molecules may eliminate leukemia without affecting the patient's nonhematopoietic cells or donor hematopoietic cells. We investigated the feasibility of this strategy using the hematopoletic system-specific minor histocompatibility antigen HA-1, which is known to induce HLA-A2-restricted CTLs. HLA-A2(-) peripheral blood mononuclear cells were stimulated with HLA-A2(+) T2 cells pulsed with synthetic HA-1 peptide or with dendritic cells transduced with the HA-1 cDNA. Tetrameric HLA-A2/HA-1 peptide complexes were used to monitor and enrich HA-1-specific CTLs. In the alloreactive cultures, HA-1-specific CTLs were enriched up to 7% by 3 rounds of antigen-specific stimulations and up to 87% by fluorescence-activated cell sorting of tetramer-positive T cells. The HA-1-specific CTLs showed specific lysis of the relevant target cells, including leukemic cells. Because the polyclonal CTL cultures also contained natural killer cells and allo-HLA-A2-specific CTLs, CTL clones were generated that showed the expected HA-1 specificity only. Thus, HA-1-specific CTLs restricted by nonself HLA-A2 molecules can be generated in an HLA-A2-mismatched setting.
引用
收藏
页码:547 / 552
页数:6
相关论文
共 50 条
  • [31] Mismatched minor histocompatibility HA-1 antigen and the development of acute graft versus host disease after HLA identical sibling bone marrow transplantation in Sardinian patients.
    Grazia, OM
    Manuela, B
    Adele, SM
    Carmen, A
    Fabiana, R
    Antonio, P
    Antonio, C
    Francesca, A
    BLOOD, 2003, 102 (11) : 478A - 478A
  • [32] Interindividual conservation of T-cell receptor beta-chain variable region (tcrbv) repertoire by in vitro generated minor histocompatibility antigen ha-1-specific Cytotoxic T-cells (CTL's)
    Verdijk, RM
    Mutis, T
    Kamp, J
    Schrama, E
    Brand, A
    Wilke, M
    Goulmy, E
    BONE MARROW TRANSPLANTATION, 2001, 27 : S111 - S111
  • [33] Cytotoxic minor histocompatibility antigen HA-1-specific CD8+ effector memory T cells:: artificial APCs pave the way for clinical application by potent primary in vitro induction
    Schilbach, K
    Kerst, G
    Walter, S
    Eyrich, M
    Wernet, D
    Handgretinger, R
    Xie, WD
    Rammensee, HG
    Müller, I
    Bühring, HJ
    Niethammer, D
    BLOOD, 2005, 106 (01) : 144 - 149
  • [34] Virus-specific T cells for adenovirus infection after stem cell transplantation are highly effective and class II HLA restricted
    Rubinstein, Jeremy D.
    Zhu, Xiang
    Leemhuis, Thomas
    Pham, Giang
    Ray, Lorraine
    Emberesh, Sana
    Jodele, Sonata
    Thomas, Shawn
    Cancelas, Jose A.
    Bollard, Catherine M.
    Hanley, Patrick J.
    Keller, Michael D.
    Grimley, Olivia
    Clark, Diana
    Clark, Teri
    Arlehamn, Cecilia S. Lindestam
    Sette, Alessandro
    Davies, Stella M.
    Nelson, Adam S.
    Grimley, Michael S.
    Lutzko, Carolyn
    BLOOD ADVANCES, 2021, 5 (17) : 3309 - 3321
  • [35] CAR T or NK cells targeting mismatched HLA-DR molecules in acute myeloid leukemia after allogeneic hematopoietic stem cell transplant
    Ikeda, Shunya
    Hasegawa, Kana
    Kogue, Yosuke
    Arimori, Takao
    Kawamoto, Ryuhei
    Wibowo, Tansri
    Yaga, Moto
    Inada, Yuri
    Uehara, Hirofumi
    Matsubara, Miwa
    Tachikawa, Mana
    Suga, Makiko
    Kida, Shuhei
    Shibata, Kumi
    Tsutsumi, Kazuhito
    Fukushima, Kentaro
    Fujita, Jiro
    Ueda, Tomoaki
    Kusakabe, Shinsuke
    Hino, Akihisa
    Ichii, Michiko
    Hirose, Asao
    Nakamae, Hirohisa
    Hino, Masayuki
    Nakao, Takafumi
    Inoue, Megumu
    Yoshihara, Kyoko
    Yoshihara, Satoshi
    Ueda, Shuji
    Tachi, Tetsuro
    Kuroda, Hideki
    Murakami, Koki
    Kijima, Noriyuki
    Kishima, Haruhiko
    Igashira, Eri
    Murakami, Mari
    Takiuchi, Tsuyoshi
    Kimura, Tadashi
    Hiroshima, Takashi
    Kimura, Toru
    Shintani, Yasushi
    Imai, Chihaya
    Yusa, Kosuke
    Mori, Ryota
    Ogino, Takayuki
    Eguchi, Hidetoshi
    Takeda, Kiyoshi
    Oji, Yusuke
    Kumanogoh, Atsushi
    Takagi, Junichi
    NATURE CANCER, 2025, : 595 - 611
  • [36] INTERINDIVIDUAL CONSERVATION OF T-CELL RECEPTOR-BETA CHAIN VARIABLE REGIONS BY MINOR HISTOCOMPATIBILITY ANTIGEN-SPECIFIC HLA-A-ASTERISK-0201-RESTRICTED CYTOTOXIC T-CELL CLONES
    GOULMY, E
    POOL, J
    VANDENELSEN, PJ
    BLOOD, 1995, 85 (09) : 2478 - 2481
  • [37] Generation of helper and cytotoxic CD4+T cell clones specific for the minor histocompatibility antigen H-Y, after in vitro priming of human T cells by HLA-identical monocyte-derived dendritic cells
    Eljaafari, A
    Farre, A
    Duperrier, K
    Even, J
    Vie, H
    Michallet, M
    Souillet, G
    Freidel, AC
    Gebuhrer, L
    Rigal, D
    TRANSPLANTATION, 2001, 71 (10) : 1449 - 1455
  • [38] Establishment of cytotoxic T lymphocytes specific for an HLA-B44-restricted CD31 antigen from an HLA-matched sibling donor in allogeneic stem cell transplantation.
    Takami, A
    Shiobara, S
    Nakao, S
    BLOOD, 2002, 100 (11) : 403B - 403B
  • [39] PHASE I CLINICAL TRIAL OF ANTI-MINOR HISTOCOMPATIBILITY ANTIGEN EXPANDED T CELLS TO TARGET LEUKEMIA RELAPSING AFTER ALLOGENEIC HLA-MATCHED TRANSPLANTATION
    Roy, D.
    Delisle, J.
    Ahmad, I.
    Leber, B.
    Couture, F.
    Thiant, S.
    Kekre, N.
    Boumedine, R. Sidi
    Carli, C.
    Brasey, A.
    Bastien, J.
    Bambace, N.
    Bernard, L.
    Cohen, S.
    Kiss, T.
    Roy, J.
    Sauvageau, G.
    Veilleux, O.
    Perreault, C.
    Busque, L.
    Lachance, S.
    CYTOTHERAPY, 2023, 25 (06) : S34 - S35
  • [40] PERSISTENCE OF MINOR HISTOCOMPATIBILITY ANTIGEN- AND VIRUS-SPECIFIC T CELLS IN LEUKEMIC REMISSION AFTER HEMATOPOIETIC ALLOGENEIC STEM CELL TRANSPLANTATION
    Schulz, Lisa Marie
    Basilio-Queiros, Debora
    Luther-Wolf, Susanne
    Dammann, Elke
    Stadler, Michael
    Mischak-Weissinger, Eva
    BONE MARROW TRANSPLANTATION, 2024, 59 : 496 - 497